GlobeNewswire Inc.··Impact BiotechImPact Biotech's Padeliporfin VTP Shows Strong 70% Response Rate in Urothelial Cancer Trial
ImPact Biotech presents Phase 3 data for padeliporfin VTP in low-grade urothelial cancer, demonstrating 70% complete response and 85.7% durability at 12 months.
IBOclinical efficacysafety profile